Givinostat
Givinostat[edit | edit source]
Givinostat is a histone deacetylase inhibitor (HDAC inhibitor) that has been studied for its potential therapeutic effects in various diseases, including cancer and inflammatory disorders. It is a small molecule that interferes with the function of histone deacetylases, enzymes that play a critical role in the regulation of gene expression by modifying the acetylation status of histones and other proteins.
Mechanism of Action[edit | edit source]
Givinostat exerts its effects by inhibiting the activity of histone deacetylases, leading to an accumulation of acetylated histones and other proteins. This results in changes in chromatin structure and the activation or repression of specific genes. The inhibition of HDACs by Givinostat can induce cell cycle arrest, promote apoptosis, and modulate immune responses.
Clinical Applications[edit | edit source]
Givinostat has been investigated in clinical trials for its potential use in treating various conditions:
- Cancer: Givinostat has shown promise in the treatment of certain types of cancer, including leukemia and lymphoma. By altering gene expression, it can inhibit the proliferation of cancer cells and induce their death.
- Inflammatory Disorders: The drug has also been studied for its effects on inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. Its ability to modulate immune responses makes it a candidate for treating these conditions.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of Givinostat involves its absorption, distribution, metabolism, and excretion. It is administered orally and undergoes hepatic metabolism. The drug's half-life and bioavailability are important factors in determining its dosing regimen.
Side Effects[edit | edit source]
Like many HDAC inhibitors, Givinostat can cause a range of side effects. Common adverse effects include gastrointestinal disturbances, fatigue, and hematological abnormalities. Monitoring and management of these side effects are crucial during treatment.
Research and Development[edit | edit source]
Ongoing research is focused on understanding the full potential of Givinostat in various therapeutic areas. Studies are exploring its use in combination with other drugs to enhance efficacy and reduce resistance.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
